ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler


ORIJINAL ARAŞTIRMA

Fibromiyalji Hastalarında Pregabalinin Kilo Alımı, Denge, Yürüme, Yorgunluk ve Uykululuk Üzerine Etkisi
The Effect of Pregabalin on Weight Gain, Balance, Gait, Fatigue and Sleepiness in Patients with Fibromyalgia
Received Date : 21 Jul 2020
Accepted Date : 02 Oct 2020
Available Online : 18 Jan 2021
Doi: 10.31609/jpmrs.2020-78190 - Makale Dili: EN
J PMR Sci. 2021;24(1):33-7
ÖZET
Amaç: Bu çalışmada 12 haftalık bir takip döneminde düşük doz pregabalinin fibromiyalji hastalarında kilo, denge, yürüyüş, yorgunluk ve uyku hâli üzerine etkisini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Fibromiyalji tanısı alan 28 hasta çalışmaya dâhil edildi. Çalışma süresince tüm hastalar 150 mg/gün pregabalin kullandı ve 12 hafta takip edildi. Tedaviye başlamadan önce, çalışmanın 4. haftasında ve 12. haftasında ağırlık, beden kitle indeksi ölçümleri, Tinetti Denge ve Yürüme Testi, Epworth Uykululuk Ölçeği ve Yorgunluk Şiddet Ölçeği uygulandı. Bu zaman noktalarında elde edilen sonuçlar birbirleriyle karşılaştırıldı. Bulgular: Çalışmaya katılmayı kabul eden 28 hastadan 11’i çalışmadan ayrıldı. Bu hastalardan 7’sinin, ayrılma sebebi yan etkilerdi. Tedavi öncesi ölçümlere göre vücut ağırlığında tedavinin 4. haftasında (p=0,010) ve 12. haftasında (p=0,008) anlamlı artış görüldü. Ortalama ağırlık artışı başlangıca göre 4. haftada 1,5±1,8 kg ve 12. haftada 1,7±1,9 kg idi. Tedavi öncesi ve sonrası değerler karşılaştırıldığında Tinetti Denge Testi, Tinetti Yürüme Testi, Epworth Uykululuk Ölçeği ve Yorgunluk Şiddet Ölçeği sonuçlarında istatistiksel olarak anlamlı bir fark saptanmadı. Sonuç: Düşük doz pregabalinin fibromiyalji hastalarında kilo alımını indüklediği, yürüyüş, denge, uykululuk ve yorgunluk üzerinde önemli bir etkisi olmadığı saptanmıştır.
ABSTRACT
Objective: Our aim was to evaluate the effect of low dose pregabalin on weight, balance, gait, fatigue, and sleepiness in fibromyalgia patients in a twelve-week follow-up period in this study. Material and Methods: Twenty-eight patients with fibromyalgia diagnosis were included in the study. All patients used 150 mg/day pregabalin during the study period and they were followed for twelve weeks. Weight, body mass index measurements, Tinetti Balance and Gait Test, Epworth Sleepiness Scale, and Fatigue Severity Scale were performed prior to the treatment, at the fourth week, and at the twelfth week of the study. The results at these time points were compared. Results: Among 28 patients who accepted to participate in the study, 11 patients dropped out of the study. Seven of these patients dropped out due to adverse effects. The weight significantly increased at the 4th (p=0.010) and 12th weeks of treatment (p=0.008) compared to the pretreatment measurements. The mean weight gain was 1.5±1.8 kg at the 4th week and 1.7±1.9 kg at the 12th week compared to the baseline. There were no statistically significant differences in the parameters of the Tinetti Balance Test, Tinetti Gait Test, Epworth Sleepiness Scale, and Fatigue Severity Scale scores before and after the treatment periods. Conclusion: Low dose pregabalin induces weight gain in patients with fibromyalgia. Pregabalin does not have a significant effect on gait, balance, sleepiness, and fatigue
REFERENCES
  1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-29.[Crossref] [PubMed] 
  2. Rahman A, Underwood M, Carnes D. Fibromyalgia. BMJ. 2014;24;348:g1224.[Crossref] [PubMed] 
  3. Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013;65(5):786-92.[Crossref] [PubMed] [PMC] 
  4. McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can. 2006;27(1):9-16.[PubMed] 
  5. Burgmer M, Pogatzki-Zahn E, Gaubitz M, Wessoleck E, Heuft G, Pfleiderer B, et al. Altered brain activity during pain processing in fibromyalgia. Neuroimage. 2009;15;44(2):502-8.[Crossref] [PubMed] 
  6. Jay GW, Barkin RL. Fibromyalgia. Dis Mon. 2015;61(3):66-111.[Crossref] [PubMed] 
  7. Evcik D, Ketenci A, Sindel D. The Turkish Society of Physical Medicine and Rehabilitation (TSPMR) guideline recommendations for the management of fibromyalgia syndrome. Turk J Phys Med Rehabil. 2019;28;65(2):111-23.[Crossref] [PubMed] [PMC] 
  8. Chinn S, Caldwell W, Gritsenko K. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep. 2016;20(4):25.[Crossref] [PubMed] 
  9. Demir G, Ediz L, Tekeoğlu İ. A randomized controlled trial of acupuncture added to escitalopram treatment for fibromyalgia and related conditions. Journal of Physical Medicine and Rehabilitation Sciences. 2010;13(3):93-8.[Link] 
  10. Arnold LM, Choy E, Clauw DJ, Oka H, Whalen E, Semel D, et al. An evidence-based review of pregabalin for the treatment of fibromyalgia. Curr Med Res Opin. 2018;34(8):1397-1409.[Crossref] [PubMed] 
  11. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al; Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4): 1264-73.[Crossref] [PubMed] 
  12. Goodman CW, Brett AS. Gabapentin and pregabalin for pain-is increased prescribing a cause for concern? N Engl J Med. 2017;3; 377(5):411-4.[Crossref] [PubMed] 
  13. Freynhagen R, Serpell M, Emir B, Whalen E, Parsons B, Clair A, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2015;15(1):47-57.[Crossref] [PubMed] [PMC] 
  14. Köpke S, Meyer G. The Tinetti test: Babylon in geriatric assessment. Z Gerontol Geriatr. 2006;39(4):288-91.[Crossref] [PubMed] 
  15. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119-26.[Crossref] [PubMed] 
  16. Yücel SD, Şahin F, Doğu B, Şahin Erçalık T, Kuran B, Gürsakal S, et al. Reliability and validity of the Turkish version of the Performance-Oriented Mobility Assessment I. Eur Rev Aging Phys Act. 2012;9(2):149-59.[Crossref] 
  17. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.[Crossref] [PubMed] 
  18. Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I, et al. Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath. 2008;12(2):161-8.[Crossref] [PubMed] 
  19. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-3.[Crossref] [PubMed] 
  20. Gencay-Can A, Can SS. Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. Rheumatol Int. 2012;32(1):27-31.[Crossref] [PubMed] 
  21. Cabrera J, Emir B, Dills D, Murphy TK, Whalen E, Clair A, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin. 2012;28(6):1027-37.[Crossref] [PubMed] 
  22. Griffin E, Brown JN. Pregabalin for the treatment of restless legs syndrome. Ann Pharmacother. 2016;50(7):586-91.[Crossref] [PubMed] 
  23. Çağlar Okur S, Vural M, Pekin Doğan Y, Mert M, Sayıner Çağlar N. The effect of pregabalin treatment on balance and gait in patients with chronic low back pain: a retrospective observational study. J Drug Assess. 2019;4;8(1):32-5.[Crossref] [PubMed] [PMC] 
  24. Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;8;74(23):1897-904.[Crossref] [PubMed] 
  25. Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019;21;9(1):e023600.[Crossref] [PubMed] [PMC] 
  26. Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;16;(10):CD010782.[Crossref] [PubMed]